Prior pneumococcal vaccination improves in-hospital mortality among elderly population hospitalized due to community-acquired pneumonia.

Seohyun Kim, Moon Jin Kim, Jun-Pyo Myong, Yun-Hee Lee, Bo Yeon Kim, Ahyoung Hwang, Gui Ok Kim, Sung Hwan Jeong, Hyoung Kyu Yoon, Tai Joon An, Jeong Uk Lim
Author Information
  1. Seohyun Kim: Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, Yeouido St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  2. Moon Jin Kim: Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, Yeouido St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  3. Jun-Pyo Myong: Department of Occupational and Environmental Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  4. Yun-Hee Lee: Department of Urology, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  5. Bo Yeon Kim: Healthcare Review and Assessment Committee, Health Insurance Review and Assessment Service , Wonju, Korea.
  6. Ahyoung Hwang: Quality Assessment Department, Health Insurance Review and Assessment Service , Wonju, Korea.
  7. Gui Ok Kim: Quality Assessment Administration Department, Health Insurance Review and Assessment Service , Wonju, Korea.
  8. Sung Hwan Jeong: Healthcare Review and Assessment Committee, Health Insurance Review and Assessment Service , Wonju, Korea.
  9. Hyoung Kyu Yoon: Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, Yeouido St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  10. Tai Joon An: Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, Yeouido St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ds31316@gmail.com.
  11. Jeong Uk Lim: Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, Yeouido St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. cracovian@hanmail.net.

Abstract

BACKGROUND: Pneumococcal vaccination is a preventive method to reduce pneumonia related mortality. However, real-world data on efficacy of the pneumococcal vaccine in reducing mortality is lacking, especially in elderly patients. This study was conducted to assess the effects of prior pneumococcal vaccination in elderly pneumonia patients.
METHODS: The data was procured from the Health Insurance Review and Assessment and Quality Assessment database. Hospitalized patients who met the criteria of community-acquired pneumonia (CAP) were included and they were grouped according to vaccination state. Patients were aged ≥ 65 years and treated with beta-lactam, quinolone, or macrolide. Patients were excluded when treatment outcomes were unknown.
RESULTS: A total of 4515 patients were evaluated, and 1609 (35.6%) of them were vaccinated prior to hospitalization. Mean age was 77.0 [71.0;82.0], 54.2% of them were male, and mean Charlson comorbidity index (CCI) was 3.0. The patients in the vaccinated group were younger than those in the unvaccinated group (76.0 vs. 78.0 years; P < 0.001), and showed higher in-hospital improvement (97.6 vs. 95.0%; P < 0.001) and lower 30-day mortality (2.6 vs. 5.3%; P < 0.001). After adjusting confounding factors such as age, gender, CURB score and CCI score, the vaccinated group demonstrated a significant reduction in 30-day mortality (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.41-0.81; P < 0.01) and in-hospital mortality (HR 0.53, 95% CI0.37-0.78; P < 0.001) compared to the unvaccinated group in multivariate analysis. Vaccinated group showed better 30-day survival than those in non-vaccinated group (log-rank test < 0.05).
CONCLUSIONS: Among elderly hospitalized CAP patients, prior pneumococcal vaccination was associated with improved in-hospital mortality and 30-day mortality.

Keywords

References

  1. Microorganisms. 2022 Jan 08;10(1): [PMID: 35056576]
  2. Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):457-62 [PMID: 16773389]
  3. Nat Med. 2004 Aug;10(8):811-3 [PMID: 15247911]
  4. Int J Infect Dis. 2018 Sep;74:136-144 [PMID: 30055332]
  5. Epidemiol Health. 2014 Jul 30;36:e2014008 [PMID: 25078381]
  6. Sci Rep. 2022 Sep 22;12(1):15833 [PMID: 36138123]
  7. J Clin Epidemiol. 2004 Dec;57(12):1288-94 [PMID: 15617955]
  8. Age Ageing. 2011 Nov;40(6):736-41 [PMID: 21771744]
  9. Int J Chron Obstruct Pulmon Dis. 2018 May 16;13:1599-1605 [PMID: 29805259]
  10. Eur Respir J. 2003 Feb;21(2):294-302 [PMID: 12608444]
  11. J Korean Med Sci. 2013 Jun;28(6):888-95 [PMID: 23772154]
  12. PLoS One. 2017 Jan 6;12(1):e0169368 [PMID: 28061505]
  13. Respirology. 2021 Aug;26(8):812-815 [PMID: 34173692]
  14. Lancet Reg Health Eur. 2021 Jun 03;7:100126 [PMID: 34557837]
  15. N Engl J Med. 2015 Mar 19;372(12):1114-25 [PMID: 25785969]
  16. Vaccine. 2016 Mar 18;34(13):1623-1629 [PMID: 26850759]
  17. J Infect Chemother. 2020 Jul;26(7):715-721 [PMID: 32334952]
  18. Age Ageing. 2016 Jan;45(1):41-7 [PMID: 26764393]
  19. J Korean Med Sci. 2022 Aug 01;37(30):e234 [PMID: 35916046]
  20. BMC Public Health. 2018 Oct 12;18(1):1172 [PMID: 30314498]
  21. Tuberc Respir Dis (Seoul). 2018 Jul;81(3):175-186 [PMID: 29926542]
  22. Medicine (Baltimore). 2003 May;82(3):159-69 [PMID: 12792302]
  23. Clin Infect Dis. 2018 Mar 19;66(7):1075-1085 [PMID: 29069315]
  24. Infect Chemother. 2015 Mar;47(1):41-8 [PMID: 25844262]
  25. Infect Chemother. 2015 Mar;47(1):68-79 [PMID: 25844267]
  26. Vaccine. 2020 Nov 17;38(49):7747-7755 [PMID: 33164798]

MeSH Term

Humans
Aged
Male
Female
Pneumonia, Pneumococcal
Hospital Mortality
Hospitalization
Vaccination
Treatment Outcome
Pneumococcal Vaccines
Community-Acquired Infections

Chemicals

Pneumococcal Vaccines

Word Cloud

Created with Highcharts 10.0.0mortality0patientsgroupvaccinationpneumoniaP < 0pneumococcalelderly001in-hospital30-daypriorvaccinatedvsdataAssessmentcommunity-acquiredCAPPatientsyearsageCCIunvaccinated78showed6score95%hospitalizedBACKGROUND:PneumococcalpreventivemethodreducerelatedHoweverreal-worldefficacyvaccinereducinglackingespeciallystudyconductedassesseffectsMETHODS:procuredHealthInsuranceReviewQualitydatabaseHospitalizedmetcriteriaincludedgroupedaccordingstateaged ≥ 65treatedbeta-lactamquinolonemacrolideexcludedtreatmentoutcomesunknownRESULTS:total4515evaluated1609356%hospitalizationMean77[71820]542%malemeanCharlsoncomorbidityindex3younger76higherimprovement97950%lower253%adjustingconfoundingfactorsgenderCURBdemonstratedsignificantreductionhazardratio[HR]58confidenceinterval[CI]41-08101HR53CI037-0comparedmultivariateanalysisVaccinatedbettersurvivalnon-vaccinatedlog-ranktest < 005CONCLUSIONS:AmongassociatedimprovedPriorimprovesamongpopulationdueCommunity-acquiredMortalityPneumococcusVaccine

Similar Articles

Cited By